ZIG
FDMT icon

Zuckerman Investment Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Zuckerman Investment Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,000
Closed -$174K – 152
2025
Q3 		$174K Hold
20,000
– – 0.02% 151
2025
Q2 		$74.2K Hold
20,000
– – 0.01% 154
2025
Q1 		$64.6K Hold
20,000
– – 0.01% 162
2024
Q4 		$119K Buy
+20,000
New +$157K 0.01% 150

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Zuckerman Investment Group's FDMT Position: Q4 2025 in Review

Zuckerman Investment Group sold out of 4D Molecular Therapeutics (FDMT) in Q4 2025, closing a stake of 20,000 shares — an estimated $174K sold.

Zuckerman Investment Group first reported a position in FDMT in Q4 2024 and held it in 4 quarters. The position peaked at $174K in Q3 2025. 153 funds tracked by Wall St. Rank hold FDMT as of Q4 2025.

  • Zuckerman Investment Group reported no remaining 4D Molecular Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Zuckerman Investment Group sold 20,000 4D Molecular Therapeutics shares in Q4 2025, an estimated $174K.
  • Zuckerman Investment Group first reported a position in 4D Molecular Therapeutics in Q4 2024 and held it in 4 quarters.
  • Zuckerman Investment Group's 4D Molecular Therapeutics position peaked at $174K in Q3 2025.
  • 153 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2025.

Based on Zuckerman Investment Group's 13F filing for Q4 2025, filed 13 Feb 2026.